Andreoli Michela, Tessari Michela, Pilla Maria, Valerio Enzo, Hagan Jim J, Heidbreder Christian A
Center of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, Via A. Fleming 4, 37135 Verona, Italy.
Neuropsychopharmacology. 2003 Jul;28(7):1272-80. doi: 10.1038/sj.npp.1300183. Epub 2003 Apr 16.
Drugs of abuse, including, nicotine have been shown to enhance brain reward functions in the mesocortico-limbic dopamine (DA) system in general, and the nucleus accumbens in particular. The latter occupies a prominent position in the ventral striatum and expresses a high density of DA D(3) receptors. As such, the present study aimed at investigating the effect of the selective D(3) receptor antagonist SB-277011-A on both the stable maintenance of intravenous nicotine self-administration and nicotine-triggered relapse to nicotine-seeking behavior in the rat. SB-277011-A (3-10 mg/kg i.p.) significantly reduced reinstatement of nicotine-seeking behavior without affecting nicotine self-administration per se. These results suggest that DA D(3) receptors are involved in the reinstatement of nicotine-seeking behavior independently of any interaction with the primary reinforcing effects of nicotine itself. These findings point toward the potential use of selective DA D(3) receptor antagonists for the pharmacotherapeutic management of relapse to drug-seeking behaviors.
包括尼古丁在内的滥用药物已被证明一般会增强中脑皮质-边缘多巴胺(DA)系统中的脑奖赏功能,尤其是伏隔核。伏隔核在腹侧纹状体中占据显著位置,并表达高密度的DA D(3)受体。因此,本研究旨在探讨选择性D(3)受体拮抗剂SB-277011-A对大鼠静脉注射尼古丁自我给药的稳定维持以及尼古丁引发的觅药行为复发的影响。SB-277011-A(腹腔注射3-10毫克/千克)显著降低了觅烟行为的恢复,而不影响尼古丁自身的自我给药。这些结果表明,DA D(3)受体参与了觅烟行为的恢复,与尼古丁本身的主要强化作用的任何相互作用无关。这些发现表明选择性DA D(3)受体拮抗剂在药物寻求行为复发的药物治疗管理方面具有潜在用途。